tbuckley/cabot-search huggingface dataset:
Abstract 20015: Value of Quantitative Atherosclerotic Plaque Assessment Using CCTA to Predict Lesion-specific Ischemia, Data from 407 Coronary Lesions
Authors: Ran Heo, Hyung-Bok Park, Nakazato Ryo, Iksung Cho, Heidi Gransar, Hyuk-Jae Chang, James K Min
Journal: Circulation (2014)

Introduction: While coronary computed tomographic angiography (CCTA) demonstrates high diagnostic performance for identification and exclusion of high-grade anatomic stenosis, it is unable to effectively discriminate coronary lesions that causes ischemia. Hypothesis: To study whether quantitative assessment of CCTA offer incremental information for discrimination of lesion ischemia beyond stenosis measures. Methods: 252 consecutive patients with suspected or known coronary artery disease (CAD) from 17 centers in 5 countries were enrolled (mean age 63±9 years, 71% male). Patients underwent CCTA and invasive coronary angiography (ICA), with 407 coronary lesions interrogated by invasive fractional flow reserve (FFR) at the time of maximum hyperemia. For these coronary lesions, we evaluated % diameter stenosis (%DS), % area stenosis (%AS), minimal luminal diameter (MLD, mm), minimal luminal area (MLA, mm 2 ), and plaque burden at MLA by CCTA. Plaque burden (PB, %) was defined as (vessel area–lumen area)/vessel areaх100. Lesion-specific ischemia by FFR was defined as a value ≤0.8. Results: In quantitative analysis area under the receiver operating characteristic curves (AUC) value of %DS, %AS, MLD, MLA, and PB for prediction of ischemia were 0.72 (95% confidence interval (CI) 0.68-0.77, p&lt;0.001), 0.73 (95% CI 0.68-0.77, p&lt;0.001), 0.75 (95% CI 0.70-0.79, p&lt;0.001), 0.75 (95% CI 0.70-0.79, p&lt;0.001), and 0.77 (95% CI 0.73-0.81, p&lt;0.001), respectively. PB showed significantly improved AUC when compared to % area stenosis (p=0.002). However, PB didn’t show incremental power over MLA (p=0.213). There also was no significant difference in AUC between MLA and % area stenosis (p=0.330) Conclusions: Quantitative plaque assessment using CCTA could predict lesion-specific ischemia with good discrimination. Plaque burden showed incremental value over % area stenosis for ischemia prediction.
192. Cardiac-Specific and Hypoxia-Responsive Vascular Endothelial Growth Factor Expression in Ischemic Hearts
Authors: Hua Su, Yu Huang, Alicia Barcena, Janice Arakawa-Hoyt, Shuji Joho, Richard Sievers, William Grossman, Yuet Wai Kan
Journal: Molecular Therapy (2004)

A problem associated with angiogenic gene therapy is that uncontrolled gene expression of angiogenic factors may cause several side effects, including: hemangioma formation, retinopathy, occult tumor growth and atherosclerotic plaque progression. Previously, we used the hypoxia response element (HRE) isolated from the erythropoietin (Epo) gene enhancer to render vascular endothelial growth factor (VEGF) expression responsive to hypoxia induction in vitro and in ischemic myocardium in vivo. We found in our experiment that adeno-associate viral vector (AAV) can be detected in other organs in addition to the heart after intra-myocardial injection. Thus, unwanted effects may still occur even with HRE controlled VEGF expression, since hypoxia in other tissues in patients with heart failure may results in extra-cardiac VEGF gene expression. To ensure the safety of angiogenic therapy for ischemic heart disease, it is necessary that the gene expression is cardiac specific and hypoxia responsive. In this study, we explored the feasibility of using the cardiac myosin light-chain-2v (MLC-2v) promoter and Epo HRE to mediate cardiac-specific and hypoxia-responsive VEGF gene expression. We constructed an AAV vector with MLC-2v promoter and 9 copies of Epo HRE driving VEGF (MLCVEGF) expression. Gene expression mediated by this vector was studied in vitro by transfection of this vector into a rat cardiac muscle cell line (H9c2), a rat skeletal muscle cell line (L6) and a mouse fibroblast cell line (NIH3T3), and in vivo by direct injection of the vector to normal and ischemic mouse hearts. AAV vectors with CMV driving VEGF (CMVVEGF), and 9HRE plus minimum SV40 promoter driving VEGF (H9VEGF) were used as controls. RESULTS: With MLCVEGF infection, VEGF expression is higher in H9c2 than the other two non-cardiac cell lines, and the expression is hypoxia inducible. In vivo studies indicated that MLCVEGF increased VEGF expression by 74% in ischemic heart compared to normal heart. VEGF expression was detected in liver, kidney, spleen and gonad of CMVVEGF inoculated mice by RT-PCR, but no VEGF expression was detected in organs other than heart and liver of MLCVEGF inoculated mice. CONCLUSION: Our result indicates that MLC-2v promoter and 9 copies of HRE can mediate cardiac-specific and hypoxia-inducible gene expression in vitro and in vivo. Induction of angiogenesis and improvement of cardiac function by this vector, studies currently in progress, may provide a safe approach for the treatment of ischemic heart disease.
Trial Registration to Prevent Duplicate Publication
Authors: Gerd Antes, Kay Dickersin
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial
Authors: Tadeusz Robak, Jerzy Z. Bloński, Marek Kasznicki, Maria Blasińska-Morawiec, Euzebiusz Krykowski, Anna Dmoszyńska, Halina Mrugala-Śpiewak, Aleksander B. Skotnicki, Wieslaw Nowak, Lech Konopka, Bernadeta Ceglarek, Stanislaw Maj, Jadwiga Dwilewicz-Trojaczek, Andrzej Hellmann, Ignacy Urasiński, Barbara Zdziarska, Sabina Kotlarek-Haus, Stanislaw Potoczek, Pawel Grieb
Journal: Blood (2000)
Abstract 2817: DCVex(TM): A novel DC-targeted vector platform for cancer immunotherapy
Authors: Tina C. Albershardt, Semih U. Tareen, Jared M. Odegard, David J. Campbell, Patrick Flynn, Scott H. Robbins, Peter Berglund, Jan H. ter Meulen
Journal: Cancer Research (2014)

Abstract Dendritic cells (DCs) are essential for the initiation of T cell responses and are therefore an attractive target for cancer immunotherapy. The DC vaccine, Provenge®, as well as a number of on-going clinical trials, have in principle validated this concept. However, the currently pursued strategy of ex vivo immunization of DCs is time-consuming and costly. We have developed a 3rd generation, integration-deficient lentivector platform, DCVex(TM), which is designed to deliver tumor antigen-encoding genes directly to DCs in vivo by targeting the DC-SIGN receptor. Mice immunized with DCVex(TM) vectors expressing a variety of model antigens developed strong, dose-dependent poly-functional and cytotoxic antigen-specific CD8 T cell responses, as assessed by intracellular cytokine staining and in vitro cytotoxic T lymphocyte assays. Repeated immunizations resulted in boosting of the T cell responses, indicating the absence of induction of inhibitory anti-vector immunity. Importantly, in stringent therapeutic tumor models (e.g., B16F10 footpad melanoma and CT26 lung metastasis models), immunization with tumor antigen-encoding vectors protected the majority of animals from death in a dose-dependent manner. These findings demonstrate the potential of DCVex(TM) as a novel cancer vaccine platform suitable for in vivo DC immunization. Citation Format: Tina C. Albershardt, Semih U. Tareen, Jared M. Odegard, David J. Campbell, Patrick Flynn, Scott H. Robbins, Peter Berglund, Jan H. ter Meulen. DCVex(TM): A novel DC-targeted vector platform for cancer immunotherapy. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2817. doi:10.1158/1538-7445.AM2014-2817
Optimizing Hemodynamics in Heart Failure Patients by Systematic Screening of Left Ventricular Pacing Sites
Authors: Nicolas Derval, Paul Steendijk, Lorne J. Gula, Antoine Deplagne, Julien Laborderie, Frederic Sacher, Sebastien Knecht, Matthew Wright, Isabelle Nault, Sylvain Ploux, Philippe Ritter, Pierre Bordachar, Stephane Lafitte, Patricia Réant, George J. Klein, Sanjiv M. Narayan, Stephane Garrigue, Mélèze Hocini, Michel Haissaguerre, Jacques Clementy, Pierre Jaïs
Journal: Journal of the American College of Cardiology (2009)
UNUSUAL REACTION TO THORAZINE
Authors: M HERSHKOWITZ
Journal: Annals of Internal Medicine (1957)

Case Reports1 April 1957UNUSUAL REACTION TO THORAZINEMELVIN HERSHKOWITZ, M.D.MELVIN HERSHKOWITZ, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-46-4-788 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAdvances in clinical pharmacology and changing therapeutic fashions of the day may influence physicians to use a particular drug when there is no clear and genuine need for its administration. This report illustrates the problem, and emphasizes the possibility that unexpected untoward effects may intrude upon an illness and complicate what might otherwise be a smooth and safe recovery.CASE REPORTA 56 year old woman had been seen a number of times in the office, mainly for recurrent bronchitis. She had a grade II apical systolic murmur, a normal chest x-ray without cardiac enlargement or pulmonary abnormality, and no...Bibliography1. Bockman RC: Personal communication from Smith, Kline, & French Laboratories, May 17, 1956. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication September 12, 1956.Requests for reprints should be addressed to Melvin Hershkowitz, M.D., 49 West Twelfth Street, New York 11, N. Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1957Volume 46, Issue 4Page: 788-790KeywordsBronchitisClinical pharmacologyDesquamationDrug administrationDrug therapyDrugsGastroenteritisNauseaSystolic ejection murmurThorax ePublished: 1 December 2008 Issue Published: 1 April 1957 PDF downloadLoading ...
Abstract 14: Examining the Predictive Power and the Impact of Incorporating Hemoglobin A1c into Existing Diabetes Risk Prediction Models among African American Adults in the Jackson Heart Study
Authors: Mary E Lacy, Gregory Wellenius, Charles B Eaton, Eric B Loucks, Adolfo Correa, Annie Gjelsvik, Wen-Chih Wu
Journal: Circulation (2014)

Background: In 2010, the American Diabetes Association (ADA) updated diagnostic criteria for diabetes to include hemoglobin A1c (A1c). However, the appropriateness of these criteria in African Americans (AAs) is unclear as A1c may not reflect glycemic control as accurately in AAs as in whites. Moreover, existing diabetes risk prediction models have been developed in populations composed primarily of whites. Objectives were to (1) examine the predictive power of existing diabetes risk prediction models in the Jackson Heart Study (JHS), a prospective cohort of 5,301 AA adults and (2) explore the impact of incorporating A1c into these models. Methods: We selected 3 widely-used diabetes risk prediction models and examined their ability to predict 5-year diabetes risk among 3,185 JHS participants free of diabetes at baseline and who returned for the 5 year follow-up visit. Incident diabetes was identified at follow-up based on current antidiabetic medications, fasting glucose ≥126 mg/dl or A1c ≥6.5%. We evaluated model performance using model discrimination (C-statistic) and reclassification (net reclassification index (NRI) and integrated discrimination improvement (IDI)). For each of the 3 models, model performance in JHS was evaluated using (1) covariates identified in the original published model and (2) published covariates plus A1c. Results: Of 3,185 participants (mean age 53.7; 64.0% female), 9.8% (n=311) developed diabetes over 5 years of follow-up. Each diabetes prediction model suffered a drop in predictive power when applied to JHS using ADA 2010 criteria (Table 1). The performance of all 3 models improved significantly with the addition of A1c, as evidenced by the increase in C-statistic and improvement in reclassification. Conclusion: Despite evidence that A1c may not accurately reflect glycemic control in AAs as well as in whites, adding A1c to existing diabetes risk prediction models developed in primarily white populations significantly improved 5-year predictive power of all 3 models among AAs in the JHS.
The Pre-Hospital Electrocardiogram and Time to Reperfusion in Patients With Acute Myocardial Infarction, 2000–2002
Authors: Jeptha P. Curtis, Edward L. Portnay, Yongfei Wang, Robert L. McNamara, Jeph Herrin, Elizabeth H. Bradley, David J. Magid, Martha E. Blaney, John G. Canto, Harlan M. Krumholz
Journal: Journal of the American College of Cardiology (2006)
New Drug for HIV-1 Infection
Authors: Bernard A. Schwetz
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A lesson learnt: Common things are common
Authors: R. Seigne
Journal: BMJ (1998)

It was my first day on the intensive care unit which made the lessons all the more memorable.

I had been asked to assess a patient who had recently been discharged back to the ward. I delegated the task to a senior house officer (SHO) explaining that he should assess the patient's condition and need for intensive care.

Half an hour later he telephoned. After describing the patient's condition he concluded that the patient would benefit from more care than the ward could provide. As our hospital has no high dependency unit for such patients an intensive care admission was required. I joined the SHO on the ward to assess the patient and to assess his clinical judgment.

From the end of the bed I saw a man who seemed to be in his late 60s …
Israel's doctors end their strike
Authors: Judy Siegel-Itzkovich
Journal: BMJ (2000)

Some 15 000 Israeli physicians in public hospitals and health fund clinics have ended 127 days of industrial action after negotiations-mediated by a team of outside experts-between the Israel Medical Association and the finance ministry.

Although the doctors won a 13.2% differential wage increase rather than the 50% increase that they had initially demanded, most were pleased because of …
377. Expression of Acid α-Glucosidase in Nonhuman Primate Diaphragm and Peritoneum after Direct In Utero Delivery of Recombinant Adeno-Associated Virus Type 1
Authors: Mary B. Rucker, Alice F. Tarantal, Thomas Conlon, Terence R. Flotte, Barry J. Byrne
Journal: Molecular Therapy (2004)

Genetic based neuromuscular disorders such as glycogen storage disease type II (GSDII), results in early and sometimes irreversible cellular damage. Deficiency in acid α-glucosidase (GAA) leads to lysosomal accumulation of glycogen in all cell types resulting in abnormal myofibrillogenesis and reduced contractile function in striated muscle. Previous studies in our laboratory showed that in utero delivery of recombinant adeno-associated virus (rAAV) encoding GAA to the peritoneal cavity of GAA-/- mice resulted in high-level transduction of diaphragm tissue. In addition, GAA-/- diaphragm transduced with rAAV-GAA in utero demonstrated near normal diaphragm muscle function when assayed at 6 months (submitted).
Potential economic savings of administration of home intravenous antibiotic therapy to patients with acute respiratory infections in Ireland
Authors: Melissa McDonnell, Maurice Power, Robert Rutherford, J.J. Gilmartin
Journal: European Respiratory Journal (2011)

Introduction:  Acute respiratory infections (ARI) account for a significant proportion of prolonged hospital stays. Intermediate care initiatives supporting home intravenous antibiotics (HIVA) aim to facilitate early discharge and avoid unnecessary admissions. Numerous studies have demonstrated the efficacy of HIVA for acute infections. International studies have shown increased patient satisfaction, improved quality of life, fewer investigations, less cross-infections, decreased social disruptions and increased cost-effectiveness.   Objective:  The purpose of this study was to analyse the potential cost-effectiveness of HIVA in patients with ARI in Ireland.   Methods:  Using the Health Service Executive (HSE) Casemix and assuming a 60% uptake of ARI patients satisfying HIVA criteria with a length of stay (LOS) of 1-3 days, cost-estimates relating to cost/bed and LOS were used to calculate cost/bed-day savings if HIVA is introduced.   Results:  The approx. annual admission rate for ARI conditions such as pneumonia, COPD, asthma, CF and bronchiectasis is 26,700 patients/yr with an average cost per admission of €70,600. Based on an average LOS of 9.2 days at a cost/bed day of €1,920, the cost/ARI admission is €17,664. This equates to €473m. An LOS of 1-3 days would result in cost-estimates of €51.4-154.2m, a gross difference of €318.8m. Accounting for expenses such as capacity, staff, training, equipment, travel and others, we estimate bed-day savings of €200-220m/yr.   Conclusion:  HIVA administration is a safe, cost-effective alternative in suitable patients with ARI, potentially providing significant savings to the health service in Ireland.
Abstract 260: Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer
Authors: Devin C. Koestler, Prabhakar Chalise, Mine S. Cicek, Julie M. Cunningham, Sebastian Armasu, Melissa C. Larson, Jeremy Chien, Matthew Block, Kimberly R. Kalli, Thomas A. Sellers, Ellen L. Goode, Brooke L. Fridley
Journal: Cancer Research (2014)

Abstract Both genetic and epigenetic factors influence the development and progression of epithelial ovarian cancer (EOC). However, there is an incomplete understanding of the interrelationship between these factors and whether they interact to impact disease risk. Given that the development of ovarian cancer is complex, we aimed to identify DNA methylation marks that are candidates for mediating ovarian cancer genetic risk. We used 214 cases and 214 age-matched controls from the Mayo Clinic Ovarian Cancer Study. Pretreatment, blood-derived DNA was profiled for genome-wide methylation (Illumina Infinium HumanMethylation27 BeadArray) and single nucleotide polymorphisms (SNPs, Illumina Infinium HD Human610-Quad BeadArray). We employed a three-step filtering procedure, followed by the Causal Inference Test (CIT), to distinguish CpG sites that mediate genetic risk, from those that are consequential or independently acted on by genotype. Controlling for the estimated distribution of immune cells and other key covariates, we identified 1,993 out of 25,926 (7.7%) CpGs that were significantly differentially methylated between cases and controls (FDR, q &amp;lt; 0.05). The relationship between methylation and case-control status among these 1,993 CpGs was found to be highly consistent with the results of an independent study. Implementation of the CIT test revealed 13 CpG/SNP pairs, comprising 13 unique CpGs and 17 unique SNPs, which represent potential methylation-mediated relationships between genotype and EOC risk. These findings provide additional insight into EOC etiology and may serve as novel biomarkers for EOC susceptibility. Citation Format: Devin C. Koestler, Prabhakar Chalise, Mine S. Cicek, Julie M. Cunningham, Sebastian Armasu, Melissa C. Larson, Jeremy Chien, Matthew Block, Kimberly R. Kalli, Thomas A. Sellers, Ellen L. Goode, Brooke L. Fridley. Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 260. doi:10.1158/1538-7445.AM2014-260
Anti-tumor activity of the heterocyclic hydrazones (HCHs), A new class of experimental antitumor agent
Authors: Lily Chu, Lanzhen Liu, Bai L. Song, Qin Wang, Yuefen Du, Xu K. Lin, Michael F. Belcourt, Ivan Ch-L. King, Li-Mou Zheng
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

4732 

Heterocyclic hydrazone derivatives reported hereby are structurally derives from alpha-(N)-heteroaromatic thiosemicarbazones (TSC). This new class of experimental antitumor agent was proven to be potent cytotoxic agents against murine and human tumor cell lines. In the present study, we have investigated 13 analogues from three series of HCHs (EPH52, EPH116, EPH135, EPH136, EPH278, EPH279, EPH280, EPH286, EPH289, EPH349, EPH350, EPH351, EPH369) by measuring in vitro anti-proliferative activity and in vivo antitumor efficacies. In vitro, these compounds showed excellent activity against a panel of murine and human tumor cell lines, including H460 human lung carcinoma, HT29 human colon carcinoma, and L1210 murine leukemia. The IC50 values of these compounds were less than 1.0 μM. These compounds also significantly inhibited the growth of H460, HT29, C8161 human melanoma, DLD-human colon carcinoma, and B16-F10 murine melanoma implanted in mice. The inhibitory effects on the growth of solid tumors varied from compound to compound, ranging from 40% to 80% over doses of 10 mg/kg to 60 mg/kg. In order to understand the mechanisms of action, three compounds (EPH278, EPH349, and EPH369) selected from three series were investigated more extensively with cellular and biochemical assays. Although the target has not been fully identified, it is possible that EPH278, EPH349, and EPH369 inhibit cell proliferation by blocking cell growth in the G0/G1 growth phase and leading to cell death by apoptosis. Our results also show that HCH compounds cause a reduction in CDK4 expression, leading to a G1 arrest in cell-cycle progression.